Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
N/A N=300 Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes
Diabetes Mellitus · Diabetes Complications
Primary: Prevalence of Hyperglycemia in the Elective Orthopedic Population — 140 patients
Early Phase 1 N=15 Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Vascular Stiffness · Insulin Sensitivity
Primary: Change in Flow Mediated Dilation (FMD) Between Baseline and After 2 Hour Insulin Clamp — 11.8; 11.8; 8.9; 8.95 % change
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
N/A N=21 Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study
Ischemic Stroke · Hyperglycemia
Primary: FVIIa — 69.7; 124.4 mU/ml
N/A N=86 Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)
Type 2 Diabetes Mellitus
Primary: Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit — 0 events
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35
N/A N=170 TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients
Hyperglycemia
Primary: Mortality — 36 mortality rate
N/A N=85 Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
Hyperglycemia · Hypoglycemia · Critical Illness
Primary: Time in Target Blood Glucose Range (BG 70-180mg/dL) — 60.5; 61.4 percentage of time within target range
Phase 4 N=27 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation
Hyperglycemia
Primary: Time to Achieve Glycemic Control — 225 Minutes
N/A N=30 Glycemic Optimization On Discharge From the Emergency Room
Diabetes Mellitus
Primary: Change in Diabetes Distress — 0; 0.5 units on a scale
N/A N=101 The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
Diabetes Mellitus, Type 2 · Medication Adherence · HYPERGLYCEMIA
Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin
Phase 4 N=72 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Hyperglycemia
Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=187 Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 Diabetes Mellitus · Colonoscopy
Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants
N/A N=35 Hyperglycemia and Mitochondrial Function in The Endothelium of Humans
Diabetes · Hyperglycemia
Primary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio
N/A N=587 Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes
Diabetes · Hypoglycemia
Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001
Phase 4 N=1,116 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
Diabetes Mellitus, Type 2 · Acute Myocardial Infarction
Primary: Number of Participants Who Experienced a Primary Combined Outcome — 174; 181 participants — p=0.866
Phase 4 N=23 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Non-Insulin-Dependent Diabetes Mellitus
Primary: Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment — 17.31; 17.53; 15.30; 10.83 Hours — p=0.064
Phase 4 N=200 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery
Postoperative Complications
Primary: Serum Blood Glucose Concentrations — 101; 137; 140; 141 mg/dl
N/A N=157 Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460
N/A N=80 Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease
Diabetes · Kidney Diseases
Primary: Mean Glucose Concentration Measured by CGM — 151.5 mg/dL
N/A N=235 Point-of-Care Glucose Testing and Insulin Supplementation
Diabetes
Primary: Mean Fasting Blood Glucose — 162; 157 mg/dL
N/A N=13 Dark Chocolate and Glucose Levels in Diabetes
Type 2 Diabetes · Type 1 Diabetes
Primary: Blood Glucose Incremental Area Under the Curve — 240.5; 83.81 mM x 120 minutes
Phase 4 N=85 Inpatient Diabetes on Corticosteroids
Diabetes Mellitus
Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl
N/A N=130 Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia
Hyperglycemias
Primary: Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours — 13.0; 22.5 hours